Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China. To learn more, visit www.stillatechnologies.com and connect with Stilla on Twitter, LinkedIn and YouTube.
< Back Home
Remi Dangla is the CEO, co-founder and inventor of technology of Stilla Technologies.
He has been named in the Top 10 Biotech entrepreneur under 30 in 2016 by Labiotech.eu, as well as a Top 10 French Innovator Under 35 by MIT Technological Review in 2014. He co founded Stilla Technologies in 2013 to build a disruptive digital PCR solution, using the microfluidic technologies he helped establish. He started his career in 2009 at the laboratory LadHyx of Ecole Polytechnique, exploring new approaches in droplet microfluidics for easy integration into innovative commercial products.